

IDEC PHARMACEUTICALS CORP / DE

Form 8-K

September 05, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

### FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): **September 5, 2002**

## IDEC PHARMACEUTICALS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**0-19311**

(Commission File Number)

**33-0112644**

(IRS Employer Identification No.)

**3030 Callan Road, San Diego, CA**

(Address of principal executive offices)

**92121**

(Zip Code)

Registrant's telephone number, including area code: **(858) 431-8500**

**N/A**

(Former name or former address, if changed since last report)

---

---

---

#### ITEM 5. Other Events.

On September 5, 2002, IDEC Pharmaceuticals Corporation (the "**Company**") announced results of Phase II clinical trials of its IDEC-114 anti-CD80 monoclonal antibody for patients with moderate-to-severe psoriasis. The Press Release announcing the Phase II results is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### ITEM 7. Financial Statements and Exhibits.

(a) Financial Statements

None.

(b) Pro Forma Financial Statements

None.

